Mumbai: Corporate hospital chain, Apollo Hospitals is moving to acquire International Finance Corporation (IFC) 31 per cent equity stakes in its retail healthcare subsidiary Apollo Health and Lifestyle for Rs 1,254 crore.
In an intimation to the stock exchange the hospital chain disclosed the, execution of definitive share purchase agreements for the acquisition of 30.58 per cent equity stake held jointly by the International Finance Corporation, Washington (IFC) and IFC EAF Apollo Investment Company (IFC EAF) in its subsidiary, Apollo Health and Lifestyle Limited (AHLL).
The deal includes purchase of over 41 crore equity stakes at a floor price of Rs 301.09 per share, aggregating into a total consideration of Rs 1,254 crore in cash and is subject to approval from the county’s fair trade regulator Competition Commission of India (CCI).
Incorporated in 2000, Apollo’s retail healthcare arm operates multispecialty clinics under the brand “Apollo Clinics” in India and the Middle East, for diabetes management, diagnostics, cradle for women and children along with centres for planned surgery.
In FY2024-25, the company’s total turn-over was at Rs 1,553 crore up from Rs 1,365 crore from the previous fiscal.
Following the completion of the proposed acquisition, AHLL will turn into a 100 per cent subsidiary of Apollo with a shareholding of 99.42 per cent, while the remaining 0.58 per cent will be held under the employee stock option (ESOP) pool.
Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Enterprise Ltd, said, “IFC has been a valuable partner providing patient capital and facilitated the growth of AHLL.”
“By bringing AHLL fully into Apollo’s fold, we are sharpening the business focus across its four verticals and will enable AHLL to scale more effectively, innovate faster, and serve patients with care models that are more personalized, accessible, and future-ready,” she said.
Besides this, the hospital chain also announced the set-up of a new 100-bed oncology centre with an investment of Rs 573 crore.
The new facility will be equipped with proton therapy and will be set up as part of the Phase 2 expansion of its upcoming 500-bed hospital in Gurugram.
As per the company release this will be Apollo’s third proton therapy installation in India, following Chennai and Hyderabad, and is under part of its plan to double the oncology business to over Rs 5,000 crore in 3–4 years.
Commenting on the announcement, Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise said, “cancer care is evolving rapidly, and at Apollo, we remain steadfast in our mission to stay ahead of this evolution. The introduction of the next generation proton therapy is a significant leap towards personalized, precise, and highly effective treatment for cancer patients.”
